Objective: To determine the incidence and prevalence of facioscapulohumeral muscular dystrophy (FSHD) in the Netherlands.
Recently, a unifying genetic model of facioscapulohumeral muscular dystrophy (FSHD) was described, thereby facilitating identification of potential therapeutic targets. 1 As clinical studies on FSHD interventions can be expected in the near future, accurate data on FSHD epidemiology are needed for trial readiness.
Several studies reported on FSHD epidemiology (figure 1, table e-1 on the Neurology ® Web site at Neurology.org); 4 were performed after genetic testing became available but did not report on population-based incidence estimates. 2 In the Netherlands, people newly diagnosed with a neuromuscular disorder are registered nationwide by 7 neuromuscular centers in CRAMP (Computer Registry of all Myopathies and Polyneuropathies). 3 This registry provides an opportunity to study frequencies of FSHD among the Dutch population.
FSHD frequencies are prone to underestimation because this disease is characterized by a high degree of clinical variability with a large proportion of individuals with mild symptoms. Moreover, relatives of persons diagnosed with FSHD may not seek medical attention. 4 We used capturerecapture methodology to estimate the total number of symptomatic individuals with FSHD by combining CRAMP data with 2 other large population-based registries. This includes those not present in any of the 3 available registries. We aim to provide an accurate estimate of FSHD incidence and prevalence in the Netherlands for a 10-year period (2001-2010) .
METHODS To estimate the total FSHD population, we applied a 3-source capture-recapture method. 5 Data regarding symptomatic persons with FSHD (with complaints and signs) were obtained from 3 sources: CRAMP; Spierziekten Nederland, the Dutch Association of Neuromuscular Diseases; and the Leiden Genetics Database (LGD) of the Department of Clinical Genetics, Leiden University Medical Center, where all genetic tests for FSHD in the Netherlands are carried out (table e-2). Date of birth, sex, and date of diagnosis were made available. CRAMP and LGD also provided the first 2 characters of the person's surname. No regional review board approval was needed due to the use of anonymous data.
In order to apply capture-recapture, symptomatic individuals from the 3 different registry sources were matched based on date of birth, sex, and, if available, the first 2 letters of the surname. When we identified multiple persons with the same date of birth and sex and the first characters of the surname were missing, date of diagnosis was used to distinguish between individuals in the matching process. Next, we sorted all persons by date of diagnosis and included those diagnosed from January 1, 2001 through December 31, 2010 (figure 2). If the dates of diagnosis were not the same for matched individuals, we used the earliest available date.
We derived a separate estimate for each year, based on date of diagnosis. Because the overlap of persons within 1 year was frequently low, we used combined numbers from the previous, current, and next year as input for the regression analyses. For this purpose, we extended the inclusion to people diagnosed in 2000 and 2011 and they were matched. Other advantages of combining data from 3 years are better convergence of the regression models and enhanced opportunities for identification of possible interaction terms.
For data analysis we applied Poisson regression, a technique for modeling occurrence of rare events in a population, using Statistical Analysis System software 9.2 (supplemental data include input and SAS syntax). 5 The modeling process started with the most saturated model possible (3 two-way interaction terms). Subsequently, nonsignificant interaction terms (p . 0.05) were removed to obtain the most parsimonious model. Decisions about removing interaction terms were based on the Wald x 2 test for significance and the log likelihood goodness of fit criterion for the total model. We based associated 95% confidence intervals (CIs) on a simple variance formula for population size estimators. 6 We derived the total numbers of affected individuals and the associated CI with the regression analyses. To obtain yearly estimates, we divided the numbers of individuals and CIs by 3. Finally, we divided the outcomes by the total number of person-years in the Dutch population in that specific year, made available by Statistics Netherlands (table e-3). 7 To estimate the prevalence in the Netherlands, the incidence rate was multiplied by the disease duration. 8 As FSHD does not decrease life expectancy, we estimated disease duration by taking the residual life expectancy based on mean age at diagnosis. Residual life expectancy data were available from Statistics Netherlands. 9
RESULTS
The results of person matching and the overlap within the registries are provided in table e-3. These formed the input for the regression models. In all but 2 years (2005 and 2007) all interaction terms were deemed nonsignificant and thus were removed from the final regression models. Also, maintaining interaction terms in 2005 and 2007 led to very high standard errors and only slightly increased the estimated numbers of affected individuals. Therefore we applied regression models without interaction terms for 2005 and 2007.
The annual incidence rates derived with the regression models varied moderately (figure 3, table e-3). On average, this was 0.3/100,000 person-years (95% CI 0.2-0.5/100,000 person-years) or 52 individuals yearly for the period 2001-2010.
The mean age at diagnosis in all registered symptomatic individuals was 42 years and the average life expectancy left was estimated to be 39 years. Therefore, we estimated the prevalence rate at 12/100,000 or 2,000 individuals with FSHD in the Netherlands. DISCUSSION By applying capture-recapture methodology using 3 large registries, we corrected for the number of symptomatic individuals with FSHD not present in any of these registries and we found a rather stable yearly incidence. The literature (table e-1) revealed 5 estimates of FSHD incidence: 3 studies reported incidence per live births and were therefore incomparable with our finding. The other available incidence estimates were 0.7 and 0.38/ 100,000 person-years. 10,e1 The latter is remarkably close to our estimate.
Several studies reported prevalence estimations between 0.21 and 6.8/100,000. Prevalences found since the introduction of genetic confirmation were on average 5/100,000 (table e-1). Our calculated prevalence estimate is more than twice as high. This reflects a large number of unidentified symptomatic individuals, possibly because they do not feel the need to seek medical attention. In the literature, availability of disease duration estimates was limited. We found an average duration of 27.9 years in Denmark, where more than 80% of the studied persons were still alive when the study closed, probably highly underestimating the duration. e2 Our estimated duration is therefore considered to be in line with this finding. Capture-recapture is based on several assumptions: a steady state in the observed population, equal probability of ascertainment for affected individuals, appropriate person matching, and registry independence. e3 Because we used 3-source capturerecapture, the last assumption does not need to be met; the interaction terms enable identification and correction of estimates. Nevertheless, the interaction terms mainly turned out to be nonsignificant, implying nondependence of the registries. The steady state assumption is never met in nationwide studies. The threat lies in nonmatching due to immigration, emigration, births, and deaths, causing overestimation of the population. By taking 1-year intervals, changes within the population were kept to a minimum, limiting any effects this nonconformation may have. Furthermore, we have no indication that the assumption about equal probability of ascertainment in the registries was violated. Finally, although the matching process of persons was based on relatively few variables, we do not expect that significant numbers of individuals were mismatched or unmatched, as FSHD is a rarely occurring disease.
Our findings show that considerable numbers of affected individuals remain undiagnosed. As the recorded mean age at diagnosis is high compared to other reports, this prevalence is possibly a lower limit. e4,e5 This suggests that FSHD is among the most prevalent neuromuscular disorders.
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Figure 3
Annual incidence of facioscapulohumeral muscular dystrophy in the Netherlands with 95% confidence intervals for the period 2001-2010
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